TY - JOUR T1 - Impact of Palifermin on Transplant Outcomes in Children and Adolescents Undergoing Allogeneic Hematopoietic Cell Transplantation JF - Anticancer Research JO - Anticancer Res SP - 6531 LP - 6537 DO - 10.21873/anticanres.14677 VL - 40 IS - 11 AU - KRZYSZTOF CZYŻEWSKI AU - ROBERT DĘBSKI AU - NATALIA BARTOSZEWICZ AU - EWA DEMIDOWICZ AU - MONIKA RICHERT-PRZYGOŃSKA AU - MONIKA ŁĘCKA AU - SONIA TARASENKO AU - JAN STYCZYŃSKI Y1 - 2020/11/01 UR - http://ar.iiarjournals.org/content/40/11/6531.abstract N2 - Background: Oral mucositis (OM) is considered to be one of the worst and most debilitating complications of conditioning for hematopoietic cell transplantation (HCT). Prevention and treatment of this complication is one of the utmost priorities of supportive therapy during transplant procedure. The objective of this study was the analysis of the influence of palifermin, keratinocyte growth factor (KGF), on transplant outcomes in patients undergoing allo-HCT. Patients and Methods: A total of 253 allo-HCTs performed between 2003-2018 in patients aged 0-19 years at a single center were analyzed. KGF was administered in 161 HCTs. Uni- and multivariate risk factor analyses were performed. Results: In spite of reducing the duration and grade of mucositis, no prognostic impact of KGF was shown for overall survival, event-free survival, relapse incidence, acute and chronic graft-versus-host disease (GVHD), nor GVHD-free relapse-free survival. Conclusion: Palifermin had no impact on transplant outcomes in children and adolescents undergoing allo-HCT. ER -